Fig. 3From: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLCFrequency of AEs grade ≥ 3, including hepatotoxicity (a), neutropenia (b), fatigue (c), vomiting (d), diarrhoea (e), nausea (f), constipation (g), elevated lipase level (h) and elevated amylase level (i) according to the ALK-TKIs type. AEs, adverse events. Asterisks indicate statistically significant differencesBack to article page